

NCLEX 2026 ▸ MATERNAL / NEWBORN ▸ HIGH YIELD

Neonatal Abstinence Syndrome

A constellation of withdrawal signs in newborns prenatally exposed to addictive substances — most commonly opioids. The nurse's role centers on early identification (Finnegan scoring), neuroprotective care, and family-centered support.

SYSTEM: MATERNAL/NEWBORN

CLUSTER: PEDIATRIC PHARMACOLOGY

NCJMM ALIGNED

2026 TEST PLAN

SOURCE DISCLOSURE: This topic was not included in the uploaded personal notes. Content compiled from standard NCLEX references: *Saunders Comprehensive Review for the NCLEX-RN (2026)*, *ATI Maternal Newborn Nursing*, *Lippincott Illustrated Reviews: Pharmacology*, the *AAP Clinical Report on Neonatal Drug Withdrawal*, and *CDC Treating for Two* guidance.

01

Definition & Overview

WHAT IT IS • WHY IT MATTERS

- ▶ **Neonatal Abstinence Syndrome (NAS)** is a drug withdrawal syndrome occurring in newborns following prenatal exposure to addictive substances that cross the placenta during pregnancy.
- ▶ **Most common cause:** maternal opioid use (heroin, methadone, buprenorphine, oxycodone, fentanyl). Also caused by SSRIs, benzodiazepines, alcohol, barbiturates, and nicotine.
- ▶ **The term Neonatal Opioid Withdrawal Syndrome (NOWS)** is used specifically when opioids are the known exposure.
- ▶ **Why it matters:** Untreated NAS can cause seizures, severe dehydration, failure to thrive, and long-term neurodevelopmental delays. Early scoring and intervention prevent escalation.

Onset: Short-Acting

- Heroin, oxycodone
- Symptoms within **24–72 hrs**
- Peak: 48–72 hrs

Onset: Long-Acting

- Methadone, buprenorphine
- Symptoms **5–7 days** after birth
- May discharge before onset

Onset: SSRI / Non-Opioid

- SSRI exposure: 24–48 hrs
- Alcohol: within 12 hrs
- Benzos: variable, delayed


02

Pathophysiology

MECHANISM • STEP BY STEP

- ▶ Maternal opioid use → drug crosses the placenta → fetus develops **physiologic dependence**.
- ▶ At birth → abrupt cessation of placental supply → CNS neurotransmitter imbalance (excess norepinephrine, dopamine, glutamate; ↓ serotonin, GABA).
- ▶ Result → **CNS hyperirritability**, autonomic instability, GI dysfunction, and respiratory dysregulation.

NAS Mechanism of Withdrawal



03

Signs & Symptoms

CNS • GI • AUTONOMIC • RESPIRATORY

CNS

- **High-pitched cry** (hallmark)
- Hyperirritability
- Tremors (disturbed & undisturbed)
- ↑ Muscle tone, hyperreflexia
- Exaggerated Moro reflex
- Poor sleep (<1–3 hrs after feed)
- Yawning, sneezing
- **Seizures** 🚑 (severe)

GI

- Poor / uncoordinated feeding
- Frantic, excessive sucking
- Vomiting, regurgitation
- Watery / loose stools
- Weight loss
- Dehydration risk

Autonomic

- Diaphoresis (sweating)
- Fever (low-grade)
- Mottling of skin
- Nasal stuffiness
- Frequent sneezing
- Lacrimation

Resp / Skin

- Tachypnea (>60/min)
- Nasal flaring
- Excoriation (knees, elbows, chin)
- Facial scratches

RED FLAGS — ESCALATE IMMEDIATELY

Seizure activity • Apnea / SpO₂ < 90% • Refusal to feed × 2 consecutive feeds • Weight loss > 10% birth weight • Severe dehydration • Finnegan score ≥ 8 on three consecutive scorings or ≥ 12 on two consecutive scorings.

FINNEGAN NEONATAL ABSTINENCE SCORING TOOL (FNAST)

Score every 3–4 HOURS (or with each feed) for the first 4–7 days. Includes 21 items across CNS, metabolic/vasomotor, and GI categories. A score ≥ 8 typically triggers pharmacologic treatment. Newer alternative: the ESC (EAT, SLEEP, CONSOLE) approach — assesses function rather than symptoms; reduces unnecessary medication.

04

Priority Nursing Interventions

ABC • SAFETY • NEUROPROTECTION

A — Airway / Breathing

- Monitor RR & SpO₂ continuously; report RR > 60
- Suction nares gently for stuffiness (bulb syringe)
- Position head of bed slightly elevated; side or supine for sleep (NEVER prone unattended — SIDS risk)
- Have suction & resuscitation equipment at bedside

C — Circulation / Hydration

- Daily weights (same scale, same time)
- Strict I&O including stool count & quality
- Monitor for dehydration: ↓ urine output, sunken fontanel, tachycardia
- IV fluids if oral intake inadequate



Neuroprotective Environment

- **Swaddle snugly** with hands midline (contains tremors)
- **Low stimulation:** dim lights, quiet voices, minimize handling
- Cluster care to allow long sleep periods
- Slow, gentle, rhythmic rocking — vertical motion
- Pacifier for non-nutritive sucking
- Skin-to-skin (kangaroo) care with stable parent



Feeding & Skin

- Small, frequent feeds (every 2–3 hrs)
- High-calorie formula (24 kcal/oz) if poor weight gain
- Breastfeeding ENCOURAGED if mom on MAT (methadone/buprenorphine) & HIV-negative & no illicit drug use
- Burp frequently; upright after feeds
- Protect skin: long sleeves, mittens, barrier cream to chin/knees



Assessment & Documentation

- Finnegan or ESC scoring every 3–4 hrs
- VS with each scoring
- Maternal urine toxicology (with consent per facility)
- Newborn urine, meconium, or umbilical cord toxicology — meconium reflects 2nd/3rd trimester exposure



Family-Centered Care

- Use nonjudgmental, trauma-informed language
- Refer mother to addiction treatment / MAT program
- Social work consult; coordinate with CPS per state law
- Teach safe sleep (ABCs of safe sleep)
- Encourage rooming-in — reduces severity & length of stay

05

Pharmacology

PHARMACOLOGIC MANAGEMENT OF NAS

DRUG / CLASS	USE / MECHANISM	KEY SIDE EFFECTS	NURSING CONSIDERATIONS
Morphine sulfate OPIOID	First-line for opioid withdrawal. Replaces deficient opioid; tapered slowly.	Respiratory depression, hypotension, sedation, constipation	Continuous RR & SpO ₂ monitoring. Have naloxone available. Wean per Finnegan scores.
Methadone LONG-ACTING OPIOID	Alternative first-line. Long half-life = stable serum levels.	Respiratory depression, QT prolongation	Monitor ECG. Slow taper over 1–2 weeks.
Buprenorphine PARTIAL AGONIST	Emerging first-line; shorter length of treatment than morphine.	Respiratory depression (ceiling effect), sedation	Sublingual route in neonates. Monitor for over-sedation.
Clonidine ALPHA-2 AGONIST	Adjunct therapy. Reduces sympathetic outflow → calms autonomic symptoms.	Hypotension, bradycardia, sedation	Monitor BP & HR. Do NOT stop abruptly — rebound hypertension.
Phenobarbital BARBITURATE	For non-opioid withdrawal (sedative/alcohol) or seizure control.	Sedation, respiratory depression, paradoxical hyperactivity	Monitor serum levels. Long half-life — risk of accumulation.
Naloxone (Narcan) ⚠️ AVOID	CONTRAINDICATED in infants of opioid-dependent mothers.	Precipitates acute, severe withdrawal & seizures	NEVER give to neonate of known opioid-using mother — even if respiratory depression at birth. Use ventilatory support instead.

⚠️ NALOXONE WARNING

Administering naloxone to an opioid-exposed neonate will precipitate **ABRUPT, SEVERE WITHDRAWAL AND SEIZURES**. If respiratory depression is present at delivery, support ventilation with bag-mask — do not reverse with naloxone.

06

NCLEX Test Traps

WHAT STUDENTS CONFUSE · PRIORITY PITFALLS

⚠️ TRAP

"The baby is crying and irritable — let's hold and rock the infant in a brightly lit nursery to soothe."

✓ CORRECT

NAS infants are **overstimulated**. Provide swaddling, dim lighting, low noise, and minimal handling. Cluster care.

⚠️ TRAP

"Mother is opioid-dependent — breastfeeding is contraindicated."

✓ CORRECT

Breastfeeding is **encouraged** if mother is on stable MAT (methadone/buprenorphine), is HIV-negative, and is not using illicit drugs. It reduces NAS severity.

⚠️ TRAP

"Newborn has respiratory depression and mother used heroin — give naloxone immediately."

✓ CORRECT

NEVER give naloxone to an opioid-exposed neonate — it precipitates acute withdrawal and seizures. Support ventilation instead.

⚠️ TRAP

"Methadone-exposed baby is fine after 48 hours — discharge home."

✓ CORRECT

Methadone withdrawal is **delayed** (onset 5–7 days). These infants need extended monitoring (often 4–7 days minimum) before discharge.

⚠️ TRAP

"Frantic sucking on the fist means the baby is hungry — feed immediately, large volumes."

✓ CORRECT

Frantic sucking is a **withdrawal sign**, not necessarily hunger. Offer pacifier first; feed small, frequent volumes; high-calorie formula if poor gain.

⚠️ TRAP

"Score is climbing — taper the morphine to wean faster."

✓ CORRECT

Pharmacologic treatment is titrated **up** if Finnegan scores rise (≥ 8 on 3 consecutive, or ≥ 12 on 2 consecutive). Wean only when scores are consistently low.

07

Patient & Family Education

DISCHARGE TEACHING • LONG-TERM CARE



Caregiving at Home

- Continue swaddling, low-stim environment, vertical rocking
- Small, frequent feeds; burp often
- Monitor weight gain weekly with pediatrician
- Recognize escalating symptoms: tremors, vomiting, fever, poor feeding → call provider



Safe Sleep (ABCs)

- **A**lone — no co-sleeping
- **B**ack — supine position to sleep
- **C**rib — firm mattress, no bumpers, blankets, or toys
- Avoid overheating; room-share for first 6–12 months



Medication Wean

- If discharged on a weaning protocol: give exact doses on schedule
- Never skip or double doses
- Follow up with neonatology / pediatrics as scheduled
- Store medications safely; lock box at home



Maternal Support

- Continue MAT program (methadone/buprenorphine clinic)
- Mental health follow-up — screen for PPD
- Connect with peer recovery support & case management
- Use nonjudgmental language; emphasize maternal–infant bonding



Long-Term Follow-Up

- Early intervention referral (developmental screening)
- Hearing & vision screening
- Monitor for ADHD, learning issues, behavioral problems in childhood
- Routine immunizations on schedule



When to Call 911 / Provider

- Seizure activity
- Stops breathing or turns blue
- Cannot be consoled, refuses 2+ feeds
- High fever, severe vomiting/diarrhea, no wet diapers in 8 hrs

08

Memory Boosters & Mnemonics

PATTERN RECOGNITION • QUICK RECALL

"WITHDRAWAL" — Classic NAS Signs

- W** **Wakefulness** (poor sleep, < 1–3 hrs)
- I** **Irritability**, high-pitched cry
- T** **Tremors**, temperature instability
- H** **Hyperactivity**, hypertonia, hyperreflexia
- D** **Diarrhea**, diaphoresis, disorganized suck
- R** **Rub marks** (excoriation), respiratory distress, rhinorrhea
- A** **Apnea**, autonomic dysfunction
- W** **Weight loss** (failure to thrive)
- A** **Alkalosis** (respiratory, from tachypnea)
- L** **Lacrimation**, low-grade fever

"SWEATER"

Short version for vital cues

- S** Sneezing, Seizures
- W** Wakefulness
- E** Excessive sucking
- A** Autonomic instability
- T** Tremors, Tachypnea
- E** Excoriation
- R** Reflexes (hyper), Rhinorrhea

"5 S's of Soothing"

Therapeutic environment

- S** **Swaddle** snugly, hands midline
- S** **Side** or stomach (only while awake/held)
- S** **Shush** — quiet environment, white noise
- S** **Swing** — slow, rhythmic vertical motion
- S** **Suck** — pacifier for non-nutritive sucking

Pattern Recognition

- **High-pitched cry** + tremors + poor feeding = NAS until proven otherwise
- Onset < 72 hrs → short-acting opioids; onset 5–7 days → methadone
- Score climbing → escalate meds; score stable low → begin wean
- Naloxone for NAS infant = WRONG ANSWER. Always.

Confusion Killers

- **NAS vs Sepsis**: NAS has hyperreflexia + sweating + high-pitched cry; sepsis has lethargy, hypotonia. *When in doubt, rule out sepsis first.*
- **Finnegan vs ESC**: Finnegan = symptom-based, every 3–4 hrs; ESC = function-based (Eats, Sleeps, Consoles)
- **FAS vs NAS**: FAS = facial features + growth restriction (alcohol). NAS = withdrawal symptoms (opioids)

09

NCJMM Clinical Judgment Scenario

SIX-STEP MODEL • NGN STYLE

CASE

A 36-hour-old term male newborn is in the well-baby nursery. Mother has a history of opioid use disorder, currently on methadone 80 mg daily. Birth weight 3.2 kg; current weight 2.95 kg. The newborn has a high-pitched cry, tremors when disturbed, loose stools × 3, and was unable to complete the last two feeds. Finnegan score this hour: 10. T 99.4°F, HR 168, RR 68, SpO₂ 96%.

STEP 1 — RECOGNIZE CUES

RECOGNIZE

Identify abnormal findings: **HIGH-PITCHED CRY**, **TREMORS**, **LOOSE STOOLS**, **POOR FEEDING × 2**, **FINNEGAN 10**, **HR 168** (tachycardia), **RR 68** (tachypnea), **WEIGHT LOSS 7.8%**, low-grade fever. Maternal history of methadone use is a key contextual cue. Note: methadone has delayed onset (5–7 days) — symptoms appearing at 36 hours may indicate additional unknown exposure or breakthrough withdrawal.

STEP 2 — ANALYZE CUES

ANALYZE

Cluster cues into NAS pattern: CNS (cry, tremors), autonomic (tachycardia, tachypnea, fever), GI (loose stools, poor feeding, weight loss). Finnegan score of 10 indicates moderate–severe withdrawal. Cues suggest **ACTIVE OPIOID WITHDRAWAL**. Rule out sepsis (similar autonomic findings) — review labs, blood culture status. Differentiate from hypoglycemia (jitteriness).

STEP 3 — PRIORITIZE HYPOTHESES

PRIORITIZE

#1 MOST LIKELY: Neonatal Abstinence Syndrome requiring pharmacologic treatment (Finnegan ≥ 8). **#2 MUST RULE OUT:** Neonatal sepsis. **#3 CONCURRENT RISKS:** Dehydration / failure to thrive, hyperthermia, ineffective parent–infant bonding.

STEP 4 — GENERATE SOLUTIONS

GENERATE

- Initiate or escalate pharmacologic therapy (morphine sulfate per protocol)
- Continue Finnegan scoring every 3–4 hrs
- Swaddle, dim lights, cluster care, reduce stimulation
- Small frequent feeds with high-calorie formula; consider IV fluids
- Daily weights, strict I&O
- Obtain sepsis workup if not already done
- Notify HCP of escalating score & vital signs
- Social work / lactation consult; review breastfeeding eligibility (methadone OK if no illicit use)

STEP 5 — TAKE ACTION

ACT

ABC PRIORITY FIRST: assess airway / RR 68 — monitor for distress, position safely. Notify provider of Finnegan 10. Administer morphine per order; document time, dose, response. Swaddle, transfer to low-stim room. Offer pacifier, attempt small feed (15–20 mL) of 24 kcal/oz formula. Document weight, I&O. Initiate sepsis precautions per facility protocol. **DO NOT** administer naloxone.

STEP 6 — EVALUATE OUTCOMES

EVALUATE

Reassess Finnegan in 3–4 hrs after intervention — expect score to trend downward. Goal: score < 8 on three consecutive scorings. Confirm feeding tolerance, weight stabilization, normothermia. If score remains ≥ 8 → escalate morphine dose. Educate & involve mother. Continue scoring until 24–48 hrs after final wean dose. Discharge planning: pediatric follow-up within 48–72 hrs.

NGN NCLEX 2026 VISUAL STUDY LIBRARY • NEONATAL ABSTINENCE SYNDROME • MATERNAL-NEWBORN CLUSTER
SOURCES: SAUNDERS 2026 • ATI MATERNAL NEWBORN • LIPPINCOTT PHARMACOLOGY • AAP • CDC TREATING FOR TWO